Related Experiment Videos
[Interferon therapy in urology].
1Klinik für Urologie Medizinischen Universität zu Lübeck.
Der Urologe. Ausg. A
|March 1, 1989
Summary
Interferons, a new class of lymphokines, show promise in urologic cancer treatment. Clinical trials indicate a 16% response rate in metastatic renal cell carcinoma, comparable to vinblastine.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Context:
- Interferons represent a novel class of lymphokines with immunomodulatory capabilities.
- Recombinant production has enabled sufficient quantities for clinical research.
- Urological applications are being explored, particularly for advanced cancers.
Purpose:
- To evaluate the efficacy of interferons in treating various urological malignancies.
- To assess the response rates of interferons in metastatic renal cell carcinoma.
- To explore potential synergistic effects with other chemotherapeutic agents.
Summary:
- Interferons have been investigated in 19 clinical reviews for metastatic renal cell carcinoma, yielding a 16% response rate (139/881 patients).
- These results are comparable to those achieved with vinblastine, with preliminary data suggesting in vitro synergy.
- Investigational use also includes superficial bladder cancer, advanced prostate cancer, and condyloma acuminata.
Impact:
- Interferons offer a new therapeutic avenue for managing urological cancers.
- The findings support further clinical trials to optimize interferon-based therapies.
- Potential combination therapies may enhance treatment outcomes in urologic oncology.